tralokinumab + topical corticosteroids (LEO Pharma)

tralokinumab + topical corticosteroids is a combination therapy regimen being evaluated for the treatment of moderate-to-severe atopic dermatitis, particularly in pediatric and infant populations. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13 (IL-13), a key T-helper 2 (Th2) cytokine that plays a central role in the pathogenesis of atopic dermatitis. By neutralizing IL-13, tralokinumab inhibits its interaction with the IL-13 receptor α1 and α2 subunits, thereby suppressing the inflammatory signaling cascade and improving skin barrier function. Topical corticosteroids (TCS) are a class of small molecule anti-inflammatory agents that function as glucocorticoid receptor agonists, providing broad suppression of skin inflammation. This combination approach is designed to provide enhanced clinical benefit over monotherapy by targeting both specific cytokine pathways and general inflammatory processes.

Brand names

AdtralzaAdbry

Other names

tralokinumab + TCS